–0.2025 < –0.2, right? [Study As­sess­ment]

posted by Helmut Homepage – Vienna, Austria, 2019-04-05 10:53  – Posting: # 20129
Views: 1,061

Hi PKS,

I reordered your quotes for clarity.

» My protocol says within (-0.20 and 0.20)
» » » Should I conclude bio-equivalence with the values of [-0.2025, 0.076] in clinical end point study.

No!
{–0.2025, +0.076} {–0.20, +0.20} ∎

Furthermore, ±0.20 of what? Since you are working with untransformed data, possibly  = ±20% of the arithmetic mean of the reference. This was used in the dark ages of BE as well. Hence, the limits were {1 – , 1 + } or {0.8000, 1.2000}. Do you think that {0.7975, 1.0760} would pass?
Or do you want to want to deal directly with (as your protocol suggests) and round the CI to only 2–3* digits in order to pass the limits stated in your own protocol?

» Can I assume it as within the interval of (-0.20, 0.20)

You can assume whatever you like. If you give us the design, sizes (per sequence in a crossover, of groups in a parallel), and the CV we can calculate the α (probability of type I error, aka patient’s risk). However, α will be >0.05 and hence, the chances that authorities will accept the study as proof of equivalence are extremely low.



Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,134 posts in 4,245 threads, 1,386 registered users;
online 20 (0 registered, 20 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 07:33 CET

A Camel is a Horse designed by committee.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5